Genasense (oblimersen, G3139)
Updated: Nov 14, 2009
| Brand Name: | Genasense |
| Generic Name: | oblimersen |
| Code Name: | G3139 |
| Company: | Genta, Inc. & Aventis |
| FDA Clinical Phase: | 3 |
Description:
Genasense is a type of antisense oligodeoxyribonucleotide. It may kill cancer cells by blocking the production of a protein that makes cancer cells live longer and by making them more sensitive to anticancer drugs.
Clinical Trials:
For a list of clinical trials studying Genasense for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official website for Genasense: http://www.genta.com/genasense/
Source: NCI Cancer Glossary, Genasense, http://www.cancer.gov/templates/db_alpha.aspx?searchTxt=Genasense (as of November 14, 2009)
Related Articles:
- Getting To Know: TNB-383B
- Dr. Christoph Driessen On Nelfinavir In The Treatment Of Multiple Myeloma
- Nelfinavir Shows Only Limited Success In Overcoming Revlimid Resistance In Multiple Myeloma Patients
- Getting To Know: Tiragolumab
- Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma